Effect of Statins on Total Cholesterol Concentrations, Cardiovascular Morbidity, and All-Cause Mortality in Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages 374-384

  Sheng, Xia ^a   Murphy, Michael J ^a   MacDonald, Thomas M ^a   Schembri, Stuart ^a   Simpson, William ^b   Winter, Janet ^c   Winter, John H ^d   Wei, Li ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c Wallacetown Health Centre   (United Kingdom)

^d NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Chronic obstructive pulmonary disease; Statins; Total cholesterol concentration

Indexed keywords

ANALGESIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TIOTROPIUM BROMIDE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MORBIDITY; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84856740300     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.014     Document Type: Article

References (25)

1. Devereux G. ABC of chronic obstructive pulmonary disease: definition, epidemiology, and risk factors. BMJ 2006, 332:1142-1144.
2. Sidney S., Sorel M., Quesenberry C.P., et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128:2068-2075.
3. Mannino D.M., Thorn D., Swensen A., Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008, 32:962-969.
4. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
5. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
6. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28:1245-1257.
7. Hunninghake D.B. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:44-49.
8. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
9. Janda S., Park K., FitzGerald J.M., et al. Statins in COPD: a systematic review. Chest 2009, 136:734-743.
10. Lee T.M., Lin M.S., Change N.C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008, 101:530-535.
11. Mancini G.B., Etminan M., Zhang B., et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47. 2554-2260.
12. van Gestel Y.R., Hoeks S.E., Sin D.D., et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008, 102:192-196.
13. Søyseth V., Brekke P.H., Smith P., Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29:279-283.
14. Walsh G.M. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med 2008, 2:329-335.
15. Murphy M.J., Wei L., Watson A.D., MacDonald T.M. "Real-life" reduction in cholesterol with statins, 1993 to 2002. Br J Clin Pharmacol 2008, 65:587-592.
16. Sheng X., Wei L., Murphy M.J., MacDonald T.M. Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study. Eur J Clin Pharmacol 2009, 65:1071-1080.
17. Wei L., Parkinson J., Macdonald T.M. The Tayside Medicines Monitoring Unit (MEMO). Pharmacoepidemiology 2005, 323-336. Wiley, Chichester, UK. 4th ed. B.L. Strom (Ed.).
18. Classification of Diseases, Functioning, and Disability Accessed January 6, 2011. http://www.cdc.gov/nchs/icd.htm.
19. Campbell M.J., Swinscow T.D.V. Statistics at Square One 2009, Wiley-Blackwell, Chichester, UK. 11th ed.
20. Campbell M.J. Statistics at Square One 2006, Wiley-Blackwell, Chichester, UK. 2nd ed.
21. Scottish Index of Multiple Deprivation Accessed January 6, 2011. http://www.scotland.gov.uk/topics/statistics/SIMD.
22. Albouaini K., Andron M., Alahmar A., Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2007, 2:535-540.
23. Egred M., Shaw S., Mohammad B., et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005, 98:493-497.
24. van Gestel Y.R., Hoeks S.E., Sin D.D., et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008, 178:695-700.
25. Short P.M., Lipworth S.I., Elder D.H., et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease:a retrospective cohort study. BMJ 2011, 342. d2549. 10.1136/bmj.d2549.